Published in J Diabetes Complications on March 04, 2005
Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med (2008) 47.90
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Vasc Health Risk Manag (2009) 0.88
Insulin glargine in the management of diabetes mellitus: an evidence-based assessment of its clinical efficacy and economic value. Core Evid (2007) 0.80
Is it possible to reduce cardiovascular risk with glucose-lowering approaches? Nat Rev Endocrinol (2009) 0.77
Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review. Vasc Health Risk Manag (2009) 0.75
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2005) 4.55
Sulodexide for kidney protection in type 2 diabetes patients with microalbuminuria: a randomized controlled trial. Am J Kidney Dis (2011) 3.81
Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care (2008) 2.57
Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. Diabetes Care (2009) 2.50
Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med (2003) 2.47
Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the strong heart study. Diabetes Care (2003) 2.40
Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol (2005) 2.25
Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care (2006) 2.25
Reproducibility of glucose measurements using the glucose sensor. Diabetes Care (2002) 2.18
Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab (2006) 1.98
Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care (2007) 1.95
Obesity and dyslipidemia. Endocrinol Metab Clin North Am (2003) 1.86
Pyridorin in type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.79
Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy. J Am Soc Nephrol (2011) 1.66
Effect of blood glucose levels on prognosis in acute myocardial infarction in patients with and without diabetes, undergoing percutaneous coronary intervention. Cardiol J (2008) 1.62
High frequency of pre-diabetes, undiagnosed diabetes and metabolic syndrome among overweight Arabs in Israel. Isr Med Assoc J (2005) 1.57
Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care (2007) 1.44
A genetic and epidemiologic study of cardiovascular disease in Alaska natives (GOCADAN): design and methods. Int J Circumpolar Health (2005) 1.43
Retracted Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. Diabetes Care (2014) 1.38
Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. Clin Ther (2007) 1.37
Natural history of cardiovascular disease in patients with diabetes: role of hyperglycemia. Diabetes Care (2008) 1.35
Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol (2002) 1.34
The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. Diabetes Metab Res Rev (2010) 1.28
Changes in cardiovascular disease risk factors among American Indians. The Strong Heart Study. Ann Epidemiol (2002) 1.27
Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab (2003) 1.26
Recruitment to a clinical trial improves glycemic control in patients with diabetes. Diabetes Care (2007) 1.23
Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. J Am Coll Cardiol (2003) 1.20
Glycemic effects of moderate alcohol intake among patients with type 2 diabetes: a multicenter, randomized, clinical intervention trial. Diabetes Care (2007) 1.15
Impact of computer-generated personalized goals on HbA(1c). Diabetes Care (2002) 1.14
Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med (2004) 1.13
Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl (2004) 1.12
The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. Am Heart J (2011) 1.11
Cardiovascular disease and risk factors in three Alaskan Eskimo populations: the Alaska-Siberia project. Int J Circumpolar Health (2005) 1.10
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology (2007) 1.09
Relation of fibrinogen to cardiovascular events is independent of preclinical cardiovascular disease: the Strong Heart Study. Am Heart J (2003) 1.09
Therapy in the early stage: incretins. Diabetes Care (2011) 1.08
CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44-targeting by antibody or from knockout mice. Ann N Y Acad Sci (2007) 1.08
Maternally and zygotically provided Cdx2 have novel and critical roles for early development of the mouse embryo. Dev Biol (2010) 1.07
Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart study. Diabetes Care (2003) 1.07
Gene polymorphisms of superoxide dismutases and catalase in diabetes mellitus. BMC Med Genet (2008) 1.06
Advanced glycoxidation end products in chronic diseases-clinical chemistry and genetic background. Mutat Res (2005) 1.05
Differences in mtDNA haplogroup distribution among 3 Jewish populations alter susceptibility to T2DM complications. BMC Genomics (2008) 1.03
A successful diabetes prevention study in Eskimos: the Alaska Siberia project. Int J Circumpolar Health (2005) 1.03
Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant (2007) 1.01
Gender-specific care of diabetes mellitus: particular considerations in the management of diabetic women. Diabetes Obes Metab (2008) 1.00
Basal-state hyperinsulinemia in healthy normoglycemic adults is predictive of type 2 diabetes over a 24-year follow-up: a preliminary report. Diabetes Care (2009) 1.00
Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol (2003) 0.98
Insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 0.97
Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom? Diabetes Care (2013) 0.97
Adiponectin and the development of diabetes in patients with coronary artery disease and impaired fasting glucose. Eur J Endocrinol (2006) 0.97
Self-monitoring of blood glucose in treatment of type 2 diabetes. Diabetes Res Clin Pract (2009) 0.96
Impaired glucose-stimulated insulin secretion is coupled with exocrine pancreatic lesions in the Cohen diabetic rat. Diabetes (2007) 0.95
Predicting the 20-year diabetes incidence rate. Diabetes Metab Res Rev (2007) 0.95
The Individualized Target HbA1c: A New Method for Improving Macrovascular Risk and Glycemia Without Hypoglycemia and Weight Gain. Rev Diabet Stud (2009) 0.94
Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care (2011) 0.93
Clinical, socioeconomic, and lifestyle parameters associated with erectile dysfunction among diabetic men. Diabetes Care (2005) 0.93
The role of sulodexide in the treatment of diabetic nephropathy. Drugs (2007) 0.93
Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia. Am Heart J (2002) 0.93
Effects of isolated post-challenge hyperglycemia on mortality in American Indians: the Strong Heart Study. Ann Epidemiol (2003) 0.93
Albuminuria in recent-onset type 2 diabetes: the Strong Heart Study. Diabetes Care (2002) 0.92
Noninvasive continuous glucose monitoring using photoacoustic technology-results from the first 62 subjects. Diabetes Technol Ther (2007) 0.92
American Diabetes Association indications for statins in diabetes: is there evidence? Diabetes Care (2009) 0.92
Pioglitazone versus Rosiglitazone: Effects on Lipids, Lipoproteins, and Apolipoproteins in Head-to-Head Randomized Clinical Studies. PPAR Res (2008) 0.90
The prognostic value of different glucose abnormalities in patients with acute myocardial infarction treated invasively. Cardiovasc Diabetol (2012) 0.89
Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos (2002) 0.89
Long-term liraglutide treatment is associated with increased insulin content and secretion in β-cells, and a loss of α-cells in ZDF rats. Pharmacol Res (2013) 0.89
Different contributions of insulin resistance and beta-cell dysfunction in overweight Israeli Arabs with IFG and IGT. Diabetes Metab Res Rev (2006) 0.88
Effects of blood glucose rate of changes on perceived mood and cognitive symptoms in insulin-treated type 2 diabetes. Diabetes Care (2007) 0.88
The emerging role of NO and IGF-1 in early renal hypertrophy in STZ-induced diabetic rats. Diabetes Metab Res Rev (2011) 0.87
Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J Vasc Res (2004) 0.87
Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity or mortality? No. Diabetes Care (2009) 0.87
Lipoprotein(a) in American Indians is low and not independently associated with cardiovascular disease. The Strong Heart Study. Ann Epidemiol (2002) 0.87
Beta-glycosphingolipids improve glucose intolerance and hepatic steatosis of the Cohen diabetic rat. Am J Physiol Endocrinol Metab (2008) 0.87
Role of renal nitric oxide synthase in diabetic kidney disease during the chronic phase of diabetes. Nephron Physiol (2005) 0.87
Advances in the Science, Treatment, and Prevention of the Disease of Obesity: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care (2015) 0.86
Metabolic and genomic dissection of diabetes in the Cohen rat. Physiol Genomics (2007) 0.86
Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther (2004) 0.86
Global call for free academic movement for international dialogue. Diabetes Care (2012) 0.85
Prevalence of symptoms suggestive of gastroparesis in a cohort of patients with diabetes mellitus. J Diabetes Complications (2013) 0.85
Relationship between blood glucose control and improved cardiovascular outcome after stent implantation in diabetic patients. Cardiology (2010) 0.85
Common dyadic coping is indirectly related to dietary and exercise adherence via patient and partner diabetes efficacy. J Fam Psychol (2013) 0.84
Albuminuria: a great risk marker, but an underestimated target in diabetes. Diabetes Care (2008) 0.84
Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). Am J Cardiol (2009) 0.84
Present and future: pharmacologic treatment of obesity. J Obes (2011) 0.84
Effects of moderate intensity glycemic control after cardiac surgery. Ann Thorac Surg (2010) 0.84
Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin (2010) 0.83
Glucose intolerance, insulin resistance and metabolic syndrome in patients with stable angina pectoris. Obesity predicts coronary atherosclerosis and dysglycemia. Pol Arch Med Wewn (2008) 0.83
Effects of tamoxifen on insulin-like growth factors, IGF binding proteins and IGFBP-3 proteolysis in breast cancer patients. Anticancer Res (2003) 0.82